The Latest Breaking News from FDA

Dividend Aristocrats offer stability, reliable income, and risk mitigation, with consistent dividend growth helping to combat uncertain times. Hence, it could be wise to add top Dividend Aristocrats like Johnson & Johnson (JNJ), PepsiCo (PEP), and Kimberly-Clark (KMB) to your portfolio. Read on.

As a new analysis highlights the impact of skin tone on drug safety and efficacy, experts outline what can be done to make medical research more inclusive.

Supreme Court rejects tobacco companies' challenge against FDA's graphic health warnings on cigarette packaging and ads.

U.S. stocks were higher, with the Dow Jones index gaining more than 400 points on Monday.

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the U.S. Food and Drug Administration (FDA)

Trump’s health department pick has expressed distrust of pharmaceuticals and attacked ‘suppression of psychedelics’

The people that president-elect Donald Trump has selected to lead federal health agencies in his second administration include a retired congressman, a surgeon and a former talk-show host

Robert F. Kennedy Jr. supports Trump's FDA commissioner pick, Marty Makary, emphasizing evidence-based science and health priorities.

Psychedelic reform has hit regulatory snags lately, but the right wing could be their biggest champion